News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Strengthens investment in channels of the future to expand patient reach
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
